Clinical Trial Update: NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH) [Phase 4]

View source ↗

Summary

A Phase 4 trial of Nebido (testosterone undecanoate) for symptomatic late onset hypogonadism has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadism

Drugs mentioned

• Nebido (testosterone undecanoate)

Snippet

Sponsor: Bayer | Conditions: Hypogonadism | Phase 4 | Status: TERMINATED